The pathogenesis of alopecia areata in rodent models

被引:24
作者
McElwee, KJ
Freyschmidt-Paul, P
Sundberg, JP
Hoffmann, RO
机构
[1] Univ Marburg, Dept Dermatol, D-35033 Marburg, Germany
[2] Jackson Lab, Bar Harbor, ME 04609 USA
关键词
hair follicle; hair disease; inflammation; autoimmunity;
D O I
10.1046/j.1523-1747.2003.12164.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Rodent models of human disease provide an important tool in the investigation of genetic and environmental activation factors, disease pathogenesis, and the development of new and improved treatments. Up to 20% of aged C3H/HeJ mice and 70% of Dundee Experimental Bald Rats (DEBR) develop alopecia areata (AA), a nonscarring, inflammatory hair loss disease with a suspected autoimmune pathogenesis. These rodent models are currently employed in determining the genetic basis of AA, understanding the mechanisms of disease initiation and progression, and defining potential endogenous and environmental influences. Induction of AA by skin graft transfer between affected and unaffected mice has been employed to examine skin and immune system changes during AA pathogenesis. Manipulation of inflammatory cells in vivo indicates AA is primarily a cell mediated disease with auto-antibody production as a secondary event. Whether the AA activating factors are exogenous or endogenous antigens, or involve normal or aberrant epitope expression remains to be elucidated. However, current research suggests a self contained disease cycle involving four key events: (1) Failure of the putative anagen stage hair follicle immune privilege and exposure of hair follicle located AA inciting epitopes to the immune system; (2) Antigen presentation, costimulation, and activation of responsive lymphocytes by antigen presenting cells; (3) Activated inflammatory cell migration to, and infiltration of, hair follicles; (4) The subsequent disruptive actions of the inflammatory cell infiltrate on the hair follicles. Each of these events is vulnerable to therapeutic intervention, and rodent models will be fundamentally involved in developing new treatments for AA.
引用
收藏
页码:6 / 11
页数:6
相关论文
共 56 条
[1]  
BARKER CF, 1977, ADV IMMUNOL, V25, P1
[2]   ABNORMAL EXPRESSION OF CLASS-I AND CLASS-II MAJOR HISTOCOMPATIBILITY ANTIGENS IN ALOPECIA-AREATA - MODULATION BY TOPICAL IMMUNOTHERAPY [J].
BROCKER, EB ;
ECHTERNACHTHAPPLE, K ;
HAMM, H ;
HAPPLE, R .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1987, 88 (05) :564-568
[3]   DIRECT IMMUNOFLUORESCENCE STUDIES IN ALOPECIA-AREATA AND MALE PATTERN ALOPECIA [J].
BYSTRYN, JC ;
ORENTREICH, N ;
STENGEL, F .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1979, 73 (05) :317-320
[4]   Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans [J].
Carroll, JM ;
McElwee, KJ ;
King, LE ;
Byrne, MC ;
Sundberg, JP .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (02) :392-402
[5]   Epitope spreading: Lessons from autoimmune skin diseases [J].
Chan, LS ;
Vanderlugt, CJ ;
Hashimoto, T ;
Nishikawa, T ;
Zone, JJ ;
Black, MM ;
Wojnarowska, F ;
Stevens, SR ;
Chen, M ;
Fairley, JA ;
Woodley, DT ;
Miller, SD ;
Gordon, KB .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (02) :103-109
[6]   The human hair follicle immune system:: cellular composition and immune privilege [J].
Christoph, T ;
Müller-Röver, S ;
Audring, H ;
Tobin, DJ ;
Hermes, B ;
Cotsarelis, G ;
Rückert, R ;
Paus, R .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (05) :862-873
[8]   Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice [J].
Freyschmidt-Paul, P ;
Sundberg, JP ;
Happle, R ;
McElwee, KJ ;
Metz, S ;
Boggess, D ;
Hoffmann, R .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (01) :61-68
[9]   Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice [J].
Freyschmidt-Paul, P ;
Seiter, S ;
Zöller, M ;
König, A ;
Ziegler, A ;
Sundberg, JP ;
Happle, R ;
Hoffmann, R .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (04) :653-657
[10]  
Freyschmidt-Paul P, 2001, CURR PHARM DESIGN, V7, P213